Short telomeres are often associated with cardiovascular risk factors and age-related diseases, while the angiotensin converting enzyme (ACE) gene insertion/deletion polymorphism (DD, ID, II) has shown such associations less consistently. We hypothesized that telomere length and association of telomere length with cardiovascular risk is affected by ACE (I/D) genotype.
Methods:
We measured leucocyte telomere length (LTL) by Southern blot and analysed ACE I/D genotypes in 1249 subjects with hypertension and left ventricular hypertrophy (LVH). We examined interactions of ACE I/D genotype with LTL and cardiovascular risk.
Results:
Mean LTL in DD or ID genotype was shorter (8.15 and 8.14 kb, respectively), than in II genotype (8.27 kb, p=0.0005). This difference was significant in the younger subjects (55–64 years, p=0.02) but not in the older group (65–80 years, p=0.56 ). In DD but not I/D or II genotype, proportion of short telomeres (<5 kb) was related to Framingham risk score.
Conclusions:
Shorter LTL in genotypes DD or ID suggests a negative effect of the D allele on telomere length. Homozygocity for the D allele appears to strengthen the association of telomere length with increased cardiovascular risk in elderly hypertensive subjects with LVH.
BlackburnEH. Switching and signaling at the telomere. Cell2001; 106: 661–667.
2.
BlascoMA. Telomeres and human disease: ageing, cancer, and beyond. Nat Rev Genet2005; 6: 611–622.
3.
BenetosAOkudaKLajemiM. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension2001; 37: 381–385.
4.
JeanclosESchorkNJKyvikKO. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension2000; 36: 195–200.
5.
Martin-RuizCMGusseklooJvan HeemstD. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell2005; 4: 287–290.
6.
SchönlandSOLopezCWidmannT. Premature telomere loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. Proc Natl Acad Sci2003; 100: 13471–13476.
7.
SamaniNJBoultbyRButlerR. Telomere shortening in atherosclerosis. Lancet2001; 358: 472–473.
8.
FitzpatrickALKronmalRAGardnerJP. Leukocyte telomere length and cardiovascular disease in the Cardiovascular Health Study. Am J Epidemiol2007; 165: 14–21.
9.
EpelESBlackburnEHLinJ. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci2004; 101: 17323–17324.
10.
ValdesAMAndrewTGardnerJP. Obesity, cigarette smoking, and telomere length in women. Lancet2005; 366: 662–664.
11.
CherkasLFAvivAValdesAmHunkinJL. The effects of social status on biological aging as measured by white-blood-cell telomere length. Aging Cell2006; 5: 361–365.
12.
FyhrquistFSaijonmaaO. Renin-angiotensin system revisited. J Intern Med2008; 264: 224–236.
13.
RigatBHubertCAlhenc-GelasF. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest1990; 86: 1343–1346.
14.
Agerholm-LarsenBNordestgaardBGTybjærg-HansenA. ACE gene polymorphism in cardiovascular disease: meta-analysis of small and large studies in whites. Arterioscler Thromb Vasc Biol2000; 20: 484–492.
Sayed-TabatabaeiFAHouwing-DuistermaatJJVan DuijnCM. Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. Stroke2003; 34: 1634–1639.
17.
MontgomeryHEClarksonPDolleryCM. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation1997; 96: 741–747.
18.
StaessenJAWangJGGinocchioG. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens1997; 15: 1579–1592.
19.
DahlöfBDevereuxRKjeldsenSE. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002; 359: 995–1003.
20.
BrouiletteSSinghRKThompsonJR. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol2003; 23: 842–846.
21.
FyhrquistFSilventoinenKSaijonmaaO. Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy, the LIFE study. J Human Hypertens. 2011; 25: 711–718.
22.
MuthumalaAMontgomeryHPalmenJ. Angiotensin-converting enzyme genotype interacts with systolic blood pressure to determine coronary heart disease risk in healthy middle-aged men. Hypertension2007; 50: 348–353.
23.
FyhrquistFTiituA.SaijonmaaO. Telomere length and progression of diabetic nephropathy in patients with type 1 diabetes. J Intern Med2010; 267: 278–286.
24.
HemannMTStrongMAHaoLY. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell2001; 107: 67–77.
25.
ZouYSfeirAGryaznovSM. Does a sentinel or a subset of short telomeres determine replicative senescence?Mol Biol Cell2004; 15: 3709–3718.
26.
BendixLBendix HornPBirk JensenU. The load of short telomeres, estimated by a new method, Universal STELA, correlates with number of senescent cells. Aging Cell2010; 9: 383–397.
27.
DanserJAHSchalekampMADHBaxWA. Angiotensin-converting enzyme in the human heart. Effect of the deletion /insertion polymorphism. Circulation1995; 92: 1387–1388.
28.
Von ZglinickiT. Role of oxidative stress in telomere length regulation and replicative senescence. Ann N Y Acad Sci2000; 908: 99–110.
ImanishiTHanoTNishioI. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens2005; 23: 97–104.
31.
VasanRSDemissieSKimuraM. Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system. The Framingham Heart Study. Circulation2008; 117: 1138–1144.
32.
SahinEDePinhoRA. Linking funtional decline of telomeres, mitochondria and stem cells during aging. Nature2010; 464: 520–526.
33.
OrnishDLinJDaubenmeierJ. Increased telomerase activity and comprehensive life style. Lancet Oncol2008; 9: 1048–1057.
34.
HoubenJMJGiltayEJRius-OttenheimN. Telomere length and mortality in elderly men: the Zuthpen elderly Study. J Gerontol A Biol Sci Med Sci2011; 363: 2015–2026.
35.
GuanJZMaedaTSuganoM. Change in telomere length distribution with age in the Japanese population. Mol Cell Biochem2007; 304: 353–360.
36.
CawthonRNSmithKRO’BrienE. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet2003; 361: 393–395.
37.
RahmutulaDNakayamaTIzumiY. Angiotensin-converting enzyme gene and longevity in the Xi Jiang Uighur autonomous region of China: an association study. J Gerontol A Biol Sci Med Sci2002; 61: 918–923.
38.
YangJ-KGongY-YLianS.H. Lack of genetic association between angiotensin-converting enzyme gene insertion/deletion polymorphism and longevity in a Han Chinese population. J Renin Angiotensin Aldosterone Syst2009; 10: 115–118.
39.
KimuraMHjelmborgJVGardnerJP. Telomere length and mortality: a study of leukocytes in elderly Danish twins. Am J Epidemiol2008; 167: 799–806.
40.
HarrapSBTzourioCCambienF. The ACE gene I/D polymorphism is not associated wit the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension2003; 42: 297–303.
41.
ArnettDKDavisBRFordCE. Pharmacogenetic association of angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment. The genetics of hypertension-associated treatment (GenHAT) study. Circulation2005; 111: 3374–3383.
42.
NordestgaardBGKontulaKBennM. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenet Genomics2010; 20: 77–85.
43.
AvivAHuntSCLinJ. Impartial comparative analysis of measurement of leukocyte telomere length/DNA content by Southern blots and qPCR. Nucleic Acids Res2011; 1–5 DOI:10.1093/nar/gkr634.
